Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia

American Journal of Clinical Pathology

Volumn 145, Issue 6, 2016, Pages 769-777

  Ouyang, Juan ^a   Goswami, Maitrayee ^a,c   Peng, Jie ^a,d   Zuo, Zhuang ^a   Daver, Naval ^b   Borthakur, Gautam ^b   Tang, Guilin ^a   Medeiros, L Jeffrey ^a   Jorgensen, Jeffrey L ^a   Ravandi, Farhad ^b   Wang, Sa A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d Central South University   (China)

Author keywords

Acute myeloid leukemia; Core binding factor; Flow cytometry; Minimal residual disease; qRT PCR

Indexed keywords

CORE BINDING FACTOR; CYTARABINE; DECITABINE; FILGRASTIM; FLUDARABINE; GUADECITABINE; IDARUBICIN; TRANSCRIPTION FACTOR CBFB; TRANSCRIPTION FACTOR MYH11; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX1T1; UNCLASSIFIED DRUG;

ACUTE MYELOID LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; DIAGNOSTIC TEST ACCURACY STUDY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETER; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; INTERMETHOD COMPARISON; LEUKEMIA RELAPSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPARAMETER FLOW CYTOMETRY; POLYMERASE CHAIN REACTION SYSTEM; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; BIOSYNTHESIS; COMPARATIVE STUDY; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASM, RESIDUAL; PRESCHOOL CHILD; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CORE BINDING FACTORS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; YOUNG ADULT;

EID: 85010755770     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1093/ajcp/aqw038     Document Type: Article

References (32)

1. Byrd JC, Mrozek K, Dodge RK, , et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, , overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer, Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
2. Grimwade D, Walker H, Oliver F, , et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult, Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
3. Schlenk RF, Benner A, Krauter J, , et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741-3750.
4. Marcucci G, Mrozek K, Ruppert AS, , et al. Prognostic factors, outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer, Leukemia Group B study. J Clin Oncol. 2005;23:5705-5717.
5. Yin JA, O'Brien MA, Hills RK, , et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification, predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120:2826-2835.
6. Buonamici S, Ottaviani E, Testoni N, , et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse, may identify patients in a curable state. Blood. 2002;99:443-449.
7. Krauter J, Gorlich K, Ottmann O, , et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol. 2003;21:4413-4422.
8. Stentoft J, Hokland P, Ostergaard M, , et al. Minimal residual core binding factor AMLs by real time quantitative PCR-initial response to chemotherapy predicts event free survival, close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res. 2006;30:389-395.
9. Guieze R, Renneville A, Cayuela JM, , et al. Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience. Leukemia. 2010;24:1386-1388.
10. Perea G, Lasa A, Aventin A, , et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21), inv(16)]. Leukemia. 2006;20:87-94.
11. Morschhauser F, Cayuela JM, Martini S, , et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. J ClinOncol. 2000;18: 788-794.
12. Jurlander J, Caligiuri MA, Ruutu T, , et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood. 1996;88:2183-2191.
13. Kayser S, Schlenk RF, Grimwade D, , et al. Minimal residual disease-directed therapy in acute myeloid leukemia. Blood. 2015;125:2331-2335.
14. Buccisano F, Maurillo L, Del Principe MI, , et al. Prognostic, therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119:332-341.
15. Jorgensen JL, Chen SS. Monitoring of minimal residual disease in acute myeloid leukemia: methods, best applications. Clin Lymphoma Myeloma Leuk. 2011;11(suppl 1): S49-S53.
16. Kern W, Voskova D, Schoch C, , et al. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica. 2004;89:528-540.
17. Freeman SD, Virgo P, Couzens S, , et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31:4123-4131.
18. Terwijn M, van Putten WL, Kelder A, , et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889-3897.
19. Walter RB, Gyurkocza B, Storer BE, , et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29:137-144.
20. Walter RB, Buckley SA, Pagel JM, , et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first, second complete remission. Blood. 2013;122:1813-1821.
21. Chen X, Xie H, Wood BL, , et al. Relation of clinical response, minimal residual disease, their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33:1258-1264.
22. Jaso JM, Wang SA, Jorgensen JL, , et al. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present, future. Bone Marrow Transplant. 2014;49:1129-1138.
23. Ouyang J, Goswami M, Tang G, , et al. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. Am J Hematol. 2015;90:504-510.
24. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
25. Leroy H, de Botton S, Grardel-Duflos N, , et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia. 2005;19:367-372.
26. van der Reijden BA, Simons A, Luiten E, , et al. Minimal residual disease quantification in patients with acute myeloid leukaemia, inv(16)/CBFB-MYH11 gene fusion. Br J Haematol. 2002;118:411-418.
27. Zhu HH, Zhang XH, Qin YZ, , et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121:4056-4062.
28. Coustan-Smith E, Campana D. Should evaluation for minimal residual disease be routine in acute myeloid leukemia Curr Opin Hematol. 2013;20:86-92.
29. Guerrasio A, Pilatrino C, De Micheli D, , et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative, quantitative RT-PCR amplification of fusion transcripts. Leukemia. 2002;16:1176-1181.
30. Adriaansen HJ, Boekhorst PA, Hagemeijer AM, , et al. Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo), inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. Blood. 1993;81:3043-3051.
31. Hospital MA, Prebet T, Bertoli S, , et al. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Blood. 2014;124:1312-1319.
32. Dohner H, Estey EH, Amadori S, , et al. Diagnosis, management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-474.